Apic Bio, Inc., an American gene therapy company for treatment of rare genetic diseases, has raised US$40 million, led by Chinese early-stage venture capital group Morningside Venture Investments, according to a January 7 announcement.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?